NEUMORA THERAPEUTICS INC (NMRA) Stock Price, Quote, News and Overview
NASDAQ:NMRA - Nasdaq - US6409791000 - Common Stock - Currency: USD
NMRA Quote, Performance and Key Statistics
1.56
-0.4 (-20.41%)
The current stock price of NMRA is 1.56 USD. In the past month the price increased by 89.87%. In the past year, price decreased by -87.53%.
NMRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.4 | 722.49B | ||
| JNJ | JOHNSON & JOHNSON | 16.73 | 402.99B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.66 | 229.28B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.03 | 223.20B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 13.39 | 214.13B | ||
| MRK | MERCK & CO. INC. | 10.3 | 199.10B | ||
| PFE | PFIZER INC | 7.32 | 133.55B | ||
| SNY | SANOFI-ADR | 11.96 | 114.02B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.57 | 90.01B | ||
| GSK | GSK PLC-SPON ADR | 8.42 | 75.79B | ||
| ZTS | ZOETIS INC | 24.48 | 65.62B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 48.83 | 44.72B |
Related stock screener links
About NMRA
Company Profile
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 110 full-time employees. The company went IPO on 2023-09-15. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Company Info
NEUMORA THERAPEUTICS INC
490 Arsenal Way, Suite 200
Watertown MASSACHUSETTS US
Employees: 108
Phone: 18577600900
NEUMORA THERAPEUTICS INC / NMRA FAQ
What is the stock price of NEUMORA THERAPEUTICS INC today?
The current stock price of NMRA is 1.56 USD. The price decreased by -20.41% in the last trading session.
What is the ticker symbol for NEUMORA THERAPEUTICS INC stock?
The exchange symbol of NEUMORA THERAPEUTICS INC is NMRA and it is listed on the Nasdaq exchange.
On which exchange is NMRA stock listed?
NMRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEUMORA THERAPEUTICS INC stock?
14 analysts have analysed NMRA and the average price target is 6.94 USD. This implies a price increase of 344.62% is expected in the next year compared to the current price of 1.56. Check the NEUMORA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEUMORA THERAPEUTICS INC worth?
NEUMORA THERAPEUTICS INC (NMRA) has a market capitalization of 252.33M USD. This makes NMRA a Micro Cap stock.
How many employees does NEUMORA THERAPEUTICS INC have?
NEUMORA THERAPEUTICS INC (NMRA) currently has 108 employees.
What are the support and resistance levels for NEUMORA THERAPEUTICS INC (NMRA) stock?
NEUMORA THERAPEUTICS INC (NMRA) has a support level at 0.82 and a resistance level at 2.03. Check the full technical report for a detailed analysis of NMRA support and resistance levels.
Should I buy NEUMORA THERAPEUTICS INC (NMRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NMRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NMRA, evaluating the profitability, health, valuation and growth aspects
- NEUMORA THERAPEUTICS INC (NMRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEUMORA THERAPEUTICS INC (NMRA) Sales and EPS estimates to see what analysts future expectations are.
- NEUMORA THERAPEUTICS INC (NMRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEUMORA THERAPEUTICS INC (NMRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEUMORA THERAPEUTICS INC (NMRA) Stock Chart to make your own analysis
- NEUMORA THERAPEUTICS INC (NMRA) Latest news and press-releases to stay up to date.
Does NEUMORA THERAPEUTICS INC (NMRA) stock pay dividends?
NMRA does not pay a dividend.
When does NEUMORA THERAPEUTICS INC (NMRA) report earnings?
NEUMORA THERAPEUTICS INC (NMRA) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of NEUMORA THERAPEUTICS INC (NMRA)?
NEUMORA THERAPEUTICS INC (NMRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
What is the Short Interest ratio of NEUMORA THERAPEUTICS INC (NMRA) stock?
The outstanding short interest for NEUMORA THERAPEUTICS INC (NMRA) is 7.7% of its float. Check the ownership tab for more information on the NMRA short interest.
NMRA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NMRA. When comparing the yearly performance of all stocks, NMRA turns out to be only a medium performer in the overall market: it outperformed 59.81% of all stocks.
NMRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NMRA. No worries on liquidiy or solvency for NMRA as it has an excellent financial health rating, but there are worries on the profitability.
NMRA Financial Highlights
Over the last trailing twelve months NMRA reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS decreased by -4.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100.51% | ||
| ROE | -113% | ||
| Debt/Equity | 0 |
NMRA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 74% to NMRA. The Buy consensus is the average rating of analysts ratings from 14 analysts.